Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Reporting

In the periods set out below, revenues by major product were as follows:

	Three months ended March 31,
(In millions)	2017		2016
Product sales:
HEMOPHILIA	$	650.4	$	—
INHIBITOR THERAPIES	220.5		—
Hematology total	870.9		—
CINRYZE	225.9		164.2
ELAPRASE	140.6		123.6
FIRAZYR	128.5		128.3
REPLAGAL	109.7		103.2
VPRIV	79.8		83.6
KALBITOR	11.7		10.4
Genetic Diseases total	696.2		613.3
IMMUNOGLOBULIN THERAPIES	498.3		—
BIO THERAPEUTICS	177.9		—
Immunology total	676.2		—
VYVANSE	563.7		509.2
ADDERALL XR	64.9		98.8
Other Neuroscience	24.7		22.1
Neuroscience total	653.3		630.1
LIALDA/MEZAVANT	175.1		168.0
PENTASA	69.1		64.0
GATTEX/REVESTIVE	69.0		51.7
NATPARA	29.7		15.6
Other Internal Medicine	75.9		84.6
Internal Medicine total	418.8		383.9
Oncology total	58.3		—
Opthalmology total	38.6		—
Total Product sales	3,412.3		1,627.3
Royalties and other revenues:
SENSIPAR Royalties	38.9		37.9
3TC and ZEFFIX Royalties	14.5		15.0
ADDERALL XR Royalties	12.5		5.8
FOSRENOL Royalties	8.6		9.2
Other Royalties and Revenues	85.5		14.1
Total Royalties and other revenues	160.0		82.0
Total Revenues	$	3,572.3	$	1,709.3